PE20141351A1 - Triazolopiridinas - Google Patents

Triazolopiridinas

Info

Publication number
PE20141351A1
PE20141351A1 PE2013002378A PE2013002378A PE20141351A1 PE 20141351 A1 PE20141351 A1 PE 20141351A1 PE 2013002378 A PE2013002378 A PE 2013002378A PE 2013002378 A PE2013002378 A PE 2013002378A PE 20141351 A1 PE20141351 A1 PE 20141351A1
Authority
PE
Peru
Prior art keywords
amino
halo
phenyl
alkyl
compounds
Prior art date
Application number
PE2013002378A
Other languages
English (en)
Inventor
Volker Schulze
Dirk Kosemund
Antje Margret Wengner
Gerhard Siemeister
Detlef Stockigt
Philip Lienau
Hartmut Schirok
Hans Briem
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of PE20141351A1 publication Critical patent/PE20141351A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TRIAZOLOPIRIDINAS DE FORMULA (I) DONDE R1 ES FENILO O PIRIDILO OPCIONALMENTE SUSTITUIDO CON HALO, HIDROXI, NITRO, ENTRE OTROS; R2 ES EL COMPUESTO DE FORMULA (i) EN DONDE Q1 ES N, CH, C-ALQUILO(C1-C6), ENTRE OTROS; Q2 Y Q3 SON CADA UNO N, CH O CR5b; R5b ES HALO, CN, ALQUILO(C1-C6), ENTRE OTROS; R5a ES HALO, NITRO, ALCOXI(C1-C6), ENTRE OTROS; R3 ES H, HALOGENO, AMINO, CN, ENTRE OTROS; R4 ES H, HIDROXI, ALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS; R5 ES H. SON COMPUESTOS PREFERIDOS: N,N-DIETIL-4-{[6-(4-{[(4-FLUOROFENIL)ACETIL]AMINO}-FENIL)[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-2-IL]AMINO}-3-METOXIBENZAMIDA; N-(4-{2-[(4-CIANO-2-METOXIFENIL)-AMINO][1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL}FENIL)-2-(4-FLUOROFENIL)ACETAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA QUINASA DEL HUSO MONOPOLAR 1 (Mps-1) SIENDO UTILES EN EL TRATAMIENTO DE LEUCEMIA, LINFOMA MALIGNO, TUMORES DE CABEZA Y CUELLO
PE2013002378A 2011-04-21 2012-04-16 Triazolopiridinas PE20141351A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11163342 2011-04-21
EP11167872 2011-05-27

Publications (1)

Publication Number Publication Date
PE20141351A1 true PE20141351A1 (es) 2014-11-01

Family

ID=46124297

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002378A PE20141351A1 (es) 2011-04-21 2012-04-16 Triazolopiridinas

Country Status (39)

Country Link
US (1) US20140120087A1 (es)
EP (1) EP2699575B1 (es)
JP (1) JP5989091B2 (es)
KR (1) KR20140025470A (es)
CN (1) CN103608350B (es)
AP (1) AP3491A (es)
AR (1) AR086191A1 (es)
AU (1) AU2012244859B2 (es)
CA (1) CA2833657A1 (es)
CL (1) CL2013003044A1 (es)
CO (1) CO6801751A2 (es)
CR (1) CR20130539A (es)
CY (1) CY1116439T1 (es)
DK (1) DK2699575T3 (es)
DO (1) DOP2013000244A (es)
EA (1) EA023766B1 (es)
EC (1) ECSP13013011A (es)
ES (1) ES2539265T3 (es)
GT (1) GT201300254A (es)
HK (1) HK1190398A1 (es)
HR (1) HRP20150517T1 (es)
HU (1) HUE025496T2 (es)
IL (1) IL228704A0 (es)
JO (1) JO3040B1 (es)
MA (1) MA35049B1 (es)
ME (1) ME02143B (es)
MX (1) MX348783B (es)
MY (1) MY164939A (es)
PE (1) PE20141351A1 (es)
PL (1) PL2699575T3 (es)
PT (1) PT2699575E (es)
RS (1) RS54044B1 (es)
SA (1) SA112330466B1 (es)
SG (1) SG194003A1 (es)
SI (1) SI2699575T1 (es)
TW (1) TWI558703B (es)
UY (1) UY34034A (es)
WO (1) WO2012143329A1 (es)
ZA (1) ZA201308707B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141066A1 (es) 2011-04-21 2014-09-05 Gilead Sciences Inc Compuestos de benzotiazol
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
CA2867061A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
EP2872506A1 (en) * 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CA2914516A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
CA2914521A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
BR112015030774A2 (pt) * 2013-06-10 2017-07-25 Bayer Pharma AG novos compostos para o tratamento de câncer
CN105283178A (zh) * 2013-06-11 2016-01-27 拜耳制药股份公司 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合
DK3008062T3 (en) 2013-06-11 2017-06-12 Bayer Pharma AG PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
CN107567503B (zh) 2015-04-17 2022-03-22 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
UA125592C2 (uk) * 2017-03-16 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2008509965A (ja) 2004-08-17 2008-04-03 ガルデルマ・リサーチ・アンド・デヴェロップメント Ｐｐａｒ型受容体を活性化する新規な二芳香族化合物およびその化粧品組成物または医薬組成物における使用
US8883820B2 (en) * 2006-08-30 2014-11-11 Cellzome Ltd. Triazole derivatives as kinase inhibitors
CA2693232A1 (en) 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
EA201000341A1 (ru) 2007-08-23 2010-10-29 Астразенека Аб 2-анилинопурин-8-оны в качестве ингибиторов ttk/mps1 для лечения пролиферативных нарушений
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
AU2008328882A1 (en) * 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as PI3K inhibitors
KR20110116160A (ko) 2009-02-13 2011-10-25 포비어 파마수티칼스 카이네이스 저해제로서의 〔1,2,4〕트리아졸로〔1,5-ａ〕피리딘
ES2547328T3 (es) 2009-04-29 2015-10-05 Bayer Intellectual Property Gmbh Imidazoquinoxalinas sustituidas
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas

Also Published As

Publication number Publication date
ES2539265T3 (es) 2015-06-29
NZ616456A (en) 2015-09-25
KR20140025470A (ko) 2014-03-04
EA023766B1 (ru) 2016-07-29
UY34034A (es) 2012-11-30
MX348783B (es) 2017-06-28
ZA201308707B (en) 2016-07-27
HK1190398A1 (zh) 2014-07-04
CY1116439T1 (el) 2017-02-08
DK2699575T3 (da) 2015-06-22
TW201245194A (en) 2012-11-16
WO2012143329A1 (en) 2012-10-26
CN103608350B (zh) 2015-11-25
PL2699575T3 (pl) 2015-08-31
JO3040B1 (ar) 2016-09-05
CO6801751A2 (es) 2013-11-29
IL228704A0 (en) 2013-12-31
TWI558703B (zh) 2016-11-21
MX2013012289A (es) 2013-11-21
AU2012244859A1 (en) 2013-10-31
HRP20150517T1 (hr) 2015-06-19
DOP2013000244A (es) 2014-03-16
CR20130539A (es) 2013-12-04
CA2833657A1 (en) 2012-10-26
AR086191A1 (es) 2013-11-27
CL2013003044A1 (es) 2014-05-02
EP2699575A1 (en) 2014-02-26
AU2012244859B2 (en) 2017-06-08
EA201301181A1 (ru) 2014-08-29
AP3491A (en) 2015-12-31
SG194003A1 (en) 2013-11-29
ECSP13013011A (es) 2013-12-31
RS54044B1 (en) 2015-10-30
JP2014511887A (ja) 2014-05-19
MA35049B1 (fr) 2014-04-03
HUE025496T2 (en) 2016-04-28
GT201300254A (es) 2015-09-01
PT2699575E (pt) 2015-07-29
EP2699575B1 (en) 2015-03-25
MY164939A (en) 2018-02-15
CN103608350A (zh) 2014-02-26
AP2013007182A0 (en) 2013-10-31
US20140120087A1 (en) 2014-05-01
SI2699575T1 (sl) 2015-10-30
JP5989091B2 (ja) 2016-09-07
SA112330466B1 (ar) 2015-09-28
ME02143B (me) 2015-10-20

Similar Documents

Publication Publication Date Title
PE20141351A1 (es) Triazolopiridinas
PE20130611A1 (es) Triazolopiridinas sustituidas
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20211411A1 (es) Compuestos de anillo fusionado
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
NZ600229A (en) Triazolopyridines
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20141405A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
PE20170663A1 (es) Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
DOP2012000298A (es) Compuestos inductores de la apoptosis derivados de sulfonil carbamoil-fenoxi pirrolopiridina, útiles en el tratamiento del cancer y de enfermedades inmunes y autoinmunes
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
PE20141973A1 (es) Compuestos de heterociclilo como inhibidores de mek
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
AR074052A1 (es) Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
NI201400023A (es) Derivados de pirrolopirimidina y purina
AR077468A1 (es) Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa

Legal Events

Date Code Title Description
FC Refusal